CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cardiff Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.89−0.02 (-1.71%)
Close on Oct 19, 2026
- Market cap
- $60.58M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-8256.3%−3041.6 pts over 5 years
Net margin
-7732.0%−2456.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -13.2% | +15.4% | +10.1% | +6.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -114.5% | -28.5% | -71.5% | |
| Return on assets | -67.9% | -26.1% | -57.6% | |
| Current ratio | 5.00 | 21.79 | 3.67 | |
| Debt to equity | 0.84 | – | – | |
| Net debt to EBITDA | -0.07× | – | – | |
| Interest coverage | -24.0× | -9543.0× | – | |
| Capex to revenue | 216.1% | 57.7% | 7.4% | |
| Diluted shares | 0M | 21M | 67M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cardiff Oncology generated $163.36M from operations and spent $1.92M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$163.36M
Used
$1.92M
Capital expenditure$1.92M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7732.0%
×Asset turnover0.01×
×Equity multiplier1.24×
=Return on equity, FY2025-71.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -7732.0% | 0.01× | 1.24× | -71.5% |
| FY2024 | -6651.7% | 0.01× | 1.17× | -59.5% |
| FY2023 | -8492.0% | 0.00× | 1.12× | -47.1% |
| FY2022 | -10026.9% | 0.00× | 1.08× | -31.4% |
| FY2021 | -7880.5% | 0.00× | 1.06× | -21.1% |
| FY2020 | -5275.1% | 0.00× | 1.09× | -28.5% |
| FY2019 | -6709.7% | 0.02× | 1.57× | -188.7% |
| FY2018 | -4351.1% | 0.03× | 1.59× | -198.4% |
| FY2017 | -4928.1% | 0.02× | 2.14× | -189.6% |
| FY2016 | -10287.7% | 0.01× | 1.69× | -114.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$45.85M
- Cash generatingOperating cash flow above zero-$37.92M
- Return on assets improvedROA up on the prior year-55.7% → -47.2%
- Earnings backed by cashOperating cash flow above net income-$37.92M vs -$45.85M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.08 → 3.67
- No dilutionShare count did not rise48M → 67M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.01 → 0.01